Pannus (Chronic Superficial Keratitis) in German Shepherds — Management Guide

Practical, evidence-based guide to chronic superficial keratitis (pannus) in German Shepherds: causes, diagnosis, UV risk, treatments (topical immunosuppressives, Doggles), lifelong care and prognosis.

Quick Overview

• What it is: Chronic superficial keratitis (CSK), commonly called "pannus," is an immune-mediated inflammatory disease of the cornea characterized by blood vessel in-growth, pigment deposition, and fibrosis that can progress to visual impairment.
• Who’s at risk: German Shepherds are one of the breeds most predisposed; onset typically occurs in young adult to middle-aged dogs. Dogs living at high altitudes or in sunny climates have increased risk due to ultraviolet (UV) light exposure.
• Prognosis: With early, consistent treatment most dogs retain useful vision. Pannus is chronic and typically requires lifelong maintenance therapy; relapses are common if therapy or UV protection is stopped.

What is pannus (pathophysiology explained simply)

Pannus (CSK) is an immune-mediated disease where the dog's immune system targets corneal tissues. The inflammation is centered on the superficial stroma and arises from a mix of genetic predisposition and environmental triggers—most importantly UV light. Affected corneas develop:

• Superficial vascularization (new blood vessels)
• Pigment (melanin) deposition from the conjunctiva
• Granulation tissue and scarring

Breed-specific risk factors and prevalence

• German Shepherd Dogs (GSDs) are classically predisposed, along with Belgian Shepherds (Malinois, Tervuren) and some crossbreeds.
• Age of onset: typically 2–6 years, although cases can occur earlier or later.
• Prevalence: exact prevalence is not well defined in the general population; among ocular disease caseloads in predisposed breeds, pannus is one of the more common corneal disorders.
• Geographic risk: higher incidence and faster progression are reported in regions with high UV exposure—high altitude areas (mountainous regions), equatorial or sunny climates, and places with reflective surfaces (snow, water). Owners in such regions should be especially vigilant.

Symptoms and staging / grading

Common clinical signs:

• Redness (conjunctival hyperemia)
• Superficial corneal cloudiness or grayish-pink tissue
• Brown/black pigment on the corneal surface
• Squinting, tearing, ocular discharge
• Photophobia (sensitivity to light)
• Gradual vision impairment if the central cornea becomes involved

• Grade 1 (mild): Peripheral corneal involvement only, limited pigmentation, minimal vascularization; vision normal.
• Grade 2 (moderate): Extension toward the central cornea, more pigment and vessels, mild vision interference or photophobia.
• Grade 3 (severe): Central cornea affected, dense pigmentation/scar, marked vascularization and potential vision loss.

Diagnostic approach

Treatment options

The goal is to control immune-mediated inflammation, protect the cornea from UV triggers, and preserve vision. Therapy is tailored to disease severity.

Medical (first-line)

Surgical / Procedural

• Superficial keratectomy: removal of diseased superficial tissue can restore transparency and reduce antigenic load; best used together with immunomodulatory therapy to prevent recurrence.
• Cryotherapy / superficial keratectomy with adjunct cryoablation: can be effective but may leave scarring and requires specialist care.
• Radiation or laser therapy: rarely used, specialist-only.

Alternative and adjunctive measures

• Omega‑3 fatty acids: supportive anti-inflammatory effect; evidence is modest but safe as adjunctive therapy.
• Low-level light therapy or topical tacrolimus replacement in refractory cases — experimental/limited data.

UV protection — practical and evidence-based

• UV light is a major environmental trigger. Strict UV protection slows progression and may reduce frequency/strength of medical therapy required.
• UV-blocking goggles (Doggles or similar): recommended for daytime outdoor activity. Choose wraparound, polarized models with UV400 or equivalent rating. Fit and comfort are critical—allow the dog to try short sessions and increase wear time gradually.
• Other measures: avoid peak sun hours, provide shade, consider indoor activity on very sunny days, and use covered runs. Reflective surfaces (snow, water) increase UV exposure—extra caution in these environments.

Long-term management and monitoring

• Expect lifelong management. Most dogs require chronic topical immunomodulatory therapy (cyclosporine or tacrolimus) at least every other day; some require daily dosing.
• Regular rechecks: initially every 2–4 weeks during induction, then every 3–6 months once stable. Recheck sooner with any flare.
• Monitor IOP if topical corticosteroids are used; baseline tonometry recommended.
• Maintain UV protection consistently—stopping UV protection or immunomodulatory therapy commonly leads to relapse.
• Keep a treatment diary (dosing times, response) to help adherence and guide adjustments during vet visits.

Prognosis and quality-of-life considerations

• With early diagnosis, appropriate topical immunomodulatory therapy, and strict UV protection, most German Shepherds retain functional vision for years.
• Prognosis depends on severity at diagnosis: mild cases respond best; advanced central scarring can cause permanent visual impairment despite therapy.
• Quality of life: typically good if pain is controlled and vision preserved; many affected dogs live normal lives with long-term topical therapy and UV protection.

Living with pannus — practical daily tips

• Use prescribed topical medication consistently and as directed. Skipping doses increases relapse risk.
• Fit and use UV-blocking dog goggles for walks/outdoor play; carry a spare pair and practice positive reward-based fitting.
• Keep outdoor time in early morning/evening and in shade during high UV index periods.
• Clean discharge gently with saline or prescribed eyewash; avoid over-the-counter human eye medications unless approved by your vet.
• Monitor for signs of progression (increased pigment, cloudiness, squinting, changes in behavior) and report early.
• Store medications as instructed (some compounded drugs require refrigeration).

When to see your vet urgently

Seek immediate veterinary attention if your dog has:

• Sudden onset of squinting, pawing at the eye, or severe pain
• Thick mucopurulent discharge or signs of infection
• Evidence of corneal ulcer (staining positive), sudden cloudiness, or acute vision loss
• Red eye that worsens rapidly despite therapy

Practical treatment examples (common regimens — discuss with your vet)

• Mild peripheral pannus: topical cyclosporine 1–2% ophthalmic ointment q12–24h for induction, then q48h maintenance; UV-blocking goggles whenever outdoors.
• Moderate disease: combination induction with topical corticosteroid (e.g., prednisolone acetate 1% q8–12h) until improvement, plus topical cyclosporine q12h; taper steroid over weeks while maintaining cyclosporine long-term.
• Severe disease: referral to ophthalmology for consideration of keratectomy plus cryotherapy, plus aggressive topical immunomodulatory therapy and UV protection.

Key risks and side effects to watch for

• Topical corticosteroids: increased intraocular pressure (glaucoma), delayed corneal healing, increased susceptibility to infection.
• Topical immunomodulators: usually well tolerated; transient stinging, conjunctival hyperemia, or rare allergic reaction.
• Systemic immunosuppressives: significant systemic side effects—used only under specialist supervision.

References and further reading

• American College of Veterinary Ophthalmologists (ACVO) — owner resources and specialist directory: https://www.acvo.org/
• Merck Veterinary Manual, "Chronic superficial keratitis (pannus)" https://www.merckvetmanual.com/
• Gelatt KN. Veterinary Ophthalmology, 6th ed. (standard textbook on canine corneal disease and medical/surgical management)

Frequently Asked Questions